These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 25998591)

  • 1. Low Prevalence of Elevated ApoB Levels in Patients with Type 2 Diabetes Not Receiving Lipid-Lowering Therapy.
    Tildesley H; Fraser T; Wise S; Mazanderani A; Aydin C; Johns K; Yu E; Bondy G
    Can J Diabetes; 2009; 33(3):163-9. PubMed ID: 25998591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy.
    Mazanderani AB; Wise SJ; Tildesley HD
    Clin Biochem; 2009 Aug; 42(12):1218-21. PubMed ID: 19497316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
    Idris I; Tate H; Ahmad A; McCormack T
    J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M; Sertić J; Duraković Z
    Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH; Franken AA; Vincent HH;
    J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group.
    Connelly PW; Petrasovits A; Stachenko S; MacLean DR; Little JA; Chockalingam A
    Can J Cardiol; 1999 Apr; 15(4):428-33. PubMed ID: 10322252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes.
    Lim Y; Yoo S; Lee SA; Chin SO; Heo D; Moon JC; Moon S; Boo K; Kim ST; Seo HM; Jwa H; Koh G
    Endocrinol Metab (Seoul); 2015 Jun; 30(2):208-15. PubMed ID: 26194080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults.
    Weltman A; Despres JP; Clasey JL; Weltman JY; Wideman L; Kanaley J; Patrie J; Bergeron J; Thorner MO; Bouchard C; Hartman ML
    Metabolism; 2003 Jan; 52(1):73-80. PubMed ID: 12524665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference intervals for six lipid analytes in 8-14 year-old school children from three different ethnical groups in the Hulun Buir area of China.
    Du Y; Sun H; Li Y; Shi X; Pei D; Qi D; Wang B
    Clin Lab; 2014; 60(8):1295-300. PubMed ID: 25185414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.
    Weinstock RS; Goldberg RB; Guyton JR; Mazzone T; Polis A; Tomassini JE; Lin J; Shah A; Tershakovec AM
    J Clin Lipidol; 2008 Feb; 2(1):25-35. PubMed ID: 21291712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study.
    Lozano JV; Pallarés V; Cea-Calvo L; Llisterri JL; Fernández-Pérez C; Martí-Canales JC; Aznar J; Gil-Guillén V; Redón J;
    Curr Med Res Opin; 2008 Mar; 24(3):659-70. PubMed ID: 18218194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of several single nucleotide polymorphisms and high body mass index on serum lipid traits.
    Yin RX; Wu DF; Miao L; Htet Aung LH; Cao XL; Yan TT; Long XJ; Liu WY; Zhang L; Li M
    Biofactors; 2013; 39(3):315-25. PubMed ID: 23355348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
    Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.